A citation-based method for searching scientific literature


List of co-cited articles
224 articles co-cited >1



Times Cited
  Citation     Count
Similarity



Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
80
45

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
129
43

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
134
43

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
108
40

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
142
35

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
99
35

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol. Ther. 2017
19
63

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
602
32

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
71
32

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
323
32

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
32

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
71
32

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N. Engl. J. Med. 1993
29

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
87
29

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
66
27

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
52
24

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
64
24

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
47
24

Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J. Clin. Endocrinol. Metab. 2016
26
30

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
21

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
45
18

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
284
18


Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
56
18

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N. Engl. J. Med. 2005
18

Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.
Sarah K Lyons, Julia M Hermann, Kellee M Miller, Sabine E Hofer, Nicole C Foster, Birgit M Rami-Merhar, Grazia Aleppo, Jochen Seufert, Linda A DiMeglio, Thomas Danne,[...]. Diabetes Care 2017
20
35



Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
48
16

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
511
16

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J. Clin. Endocrinol. Metab. 2015
205
16


A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
87
16

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.
Ruth S Weinstock, Dongyuan Xing, David M Maahs, Aaron Michels, Michael R Rickels, Anne L Peters, Richard M Bergenstal, Breanne Harris, Stephanie N Dubose, Kellee M Miller,[...]. J. Clin. Endocrinol. Metab. 2013
154
16

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
301
16

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
49
16

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers,[...]. PLoS ONE 2015
22
22

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco.  2015
21
23

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
47
13

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
156
13

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Nitesh D Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, Antoine Makdissi, Manav Batra, Sartaj Sandhu, Jeanne Hejna, Kelly Green, Natalie Bellini,[...]. Diabetes Care 2016
37
13

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet. Med. 2011
79
13

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Ingrid M Libman, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Michelle L Katz, Avni Shah, Jill H Simmons, Michael J Haller, Sripriya Raman, William V Tamborlane,[...]. JAMA 2015
75
13

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
28
17

Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Robert L Dobbins, Frank L Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan M Andrews, Jeffrey A Wald, Ann Walker, Chari D Smith. Am. J. Physiol. Gastrointest. Liver Physiol. 2015
52
13

Mean amplitude of glycemic excursions, a measure of diabetic instability.
F J Service, G D Molnar, J W Rosevear, E Ackerman, L C Gatewood, W F Taylor. Diabetes 1970
596
13

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
154
10

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
123
10

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
97
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.